Clinical trial • Phase IV • Neurology
CLOZAPINE for Schizophrenia
Phase IV trial of CLOZAPINE for Schizophrenia. 200 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Schizophrenia
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 10-10-2024
- First CTIS Authorization Date
- 23-10-2024
Trial design
Phase IV trial across 1 site in Denmark.
- Target Sample Size
- 200
Eligibility
Recruits 200 No vulnerable population selected. Inclusion criterion requires participants to be "Legally competent". Informed consent documents for adults are provided (documents titled 'L1_SIS and ICF - adults -Informed consent' and 'L1_SIS and ICF - adults -Subject information'). No assent process for minors is described..
- Pregnancy Exclusion
- Pregnancy (will be verified by urine-HCG-test in fertile females)
- Vulnerable Population
- No vulnerable population selected. Inclusion criterion requires participants to be "Legally competent". Informed consent documents for adults are provided (documents titled 'L1_SIS and ICF - adults -Informed consent' and 'L1_SIS and ICF - adults -Subject information'). No assent process for minors is described.
Inclusion criteria
- {"criterion_text":"- According to ICD-10 fulfill diagnostic criteria of schizophrenia (F20.x), chronical paranoid psychoses (F22), Schizoaffective psychoses (F25) or other non-organic psychoses (F28/29)\n- Age 18-64 years\n- Legally competent\n- Stable antipsychotic treatment during the last month\n- Being treatment refractory according to TRIPP-guidelines (Howes et al. 2017) defined as having tried at least two antipsychotic drugs in sufficient dosage (≥600 mg clorpromazine equivalent) for a sufficient time (≥ 6 weeks) without sufficient symptom improvement (still a moderate level of positive symptoms).\n- Recreational use of substances is allowed as long as it does not interfere with compliance\n- Fertile females must use safe contraception (spiral or any hormonal contraception)."}
Exclusion criteria
- {"criterion_text":"- Involuntarily psychiatric admittance during the study\n- Substance abuse that interfere with compliance\n- Any condition that interfere with compliance for obtaining bloodsamples weekly\n- Pregnancy (will be verified by urine-HCG-test in fertile females)\n- Females who are breastfeeding\n- Toxic or idiosyncratic agranulocytosis in the past\n- Reduced bone marrow function according to blood samples (normal function defined as leucocytes > 3.3*109/l and neutrophil > 2.0*109/l)\n- According to information from patient and available files, no o\tCurrent uncontrolled epilepsy o\tCurrent circulatory collapse and / or CNS depression for any cause o\tCurrent severe kidney, heart or liver disease o\tCurrent paralytic ileus"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Permeability of the blood-brain barrier blood and CSF inflammatory cytokines","definition_or_measurement_approach":""}
Recruitment
- Planned Sample Size
- 200
- Recruitment Window Months
- 120
- Consent Approach
- Informed consent is obtained from legally competent adults. Documents provided include 'L1_SIS and ICF - adults -Informed consent' and 'L1_SIS and ICF - adults -Subject information'. No procedures for assent or parental consent for minors are described.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 200
Denmark
- Earliest CTIS Part Ii Submission Date
- 17-10-2024
- Latest Decision Or Authorization Date
- 23-10-2024
- Processing Time Days
- 6
- Number Of Sites
- 1
- Number Of Participants
- 200
Sites
- Site Name
- Region Hovedstadens Psykiatriske
- Department Name
- Enhed for kompliceret skizofreni
- Contact Person Name
- Jimmi Nielsen
- Contact Person Email
- jimmi.nielsen@regionh.dk
Sponsor
Primary sponsor
- Full Name
- Region Hovedstaden
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"1","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- CLOZAPINE
- Active Substance
- CLOZAPINE
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- ORAL USE
- Authorisation Status
- Authorised and marketed
- Maximum Dose
- 900 mg
Related trials
Other published trials that may interest you.